STAT3 and cancer: JIB-04, a histone demethylase inhibitor, targets epigenetic regulators involved in stemness pathways (41), while napabucasin, a STAT3 inhibitor, blocks key transcriptional pathways that promote cancer stem cell survival (42, 43).